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Immune tolerance to self antigens is an important characteristic of the immune
system. This is the mechanism by which the immune system distinguishes between
self and foreign antigens. Immune tolerance, according to Burnet's clonal selec-
tion theory, results from the deletion of lymphoid clones that produce antibodies
that can interact with self antigens (1, 2). Elimination of these autoreactive clones
occurs during an embryonic stage by an unknown mechanism . This hypothesis
has been challenged by studies (3) that have shown that human sera contain
natural antibodies against various proteins that are normally present in man.
Guilbert, Avrameas, and their colleagues (4, 5) have shown, by the use of affinity
chromatography purification methods, that normal human sera contain natural
antibodies to evolutionarily conserved proteins including cytochrome c, actin,
tubulin, fetuin, collagen, and even human albumin. Using the same approach,
Lutz et al. (6) demonstrated antibodies in human sera to the band 3 molecule of
human red cells. The occurrence ofthese autoantibodies suggest that self-reactive
clones are not eliminated by the tolerance mechanism as proposed by Burnet (1)
andJerne (2).
Due to the low concentration of these natural antibodies in human serum
(<0.5 4g/ml), and their considerable degree of crossreactivity (4, 5), these anti-
peptide antibodies may not serve as an appropriate system for the study of
immune tolerance to self antigens. Analysis of the interaction between naturally
occurring anti-carbohydrate antibodies and chemically defined carbohydrate
antigens should provide a more precise system to study the effect of immune
tolerance on the interaction between natural antibodies and selfantigens. Binding
of antibodies to glycosidic epitopes does not involve electrostatic bonds. Thus,
weak crossreactivities observed with anti-protein antibodies due to partial simi-
larities in charge arrays on various protein epitopes are avoided. Binding of the
glycosidic epitope occurs within the antibody molecule rather than on the surface,
providing a firm attachment of the uncharged epitope, in which Van der Walls
forces and hydrogen bonding constitute the dominant binding force (7). This
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TABLE I
Blood Group Antigens and Antibodies in DifferentBlood Types
type of interaction requires a high degree of structural fitting between the
antigen and the combining site on the antibody molecule.
Human anti-carbohydrate antibodies are, like other antibodies, polyclonal in
nature. The combining sites of the different clones vary in the extent of the area
complementary to the antigenic epitope (8). Nevertheless, natural anti-carbohy-
drate antibodies display a high degree of specificity. For example, the difference
in the binding specificities of anti-blood group A and B antibodies is related to
the presence or absence ofa N-acetyl residue on the terminal galactosyl of the A
and B blood group determinant (7, 9; Table I).
We have recently described (10) another natural anti-carbohydrate antibody,
anti-Gal, that also displays this same sort of narrowly defined specificity. Anti-
Gal is a polyclonal antibody present in every individual and constitutes as much
as 1% of the circulating IgG. Anti-Gal isolated from AB sera by affinity chro-
matography was found to display a distinct specificity forglycosphingolipids with
a Galal-*3Gal glycosidic epitope. However, it did not bind to closely related
glycosphingolipids with a Gala 1---*3(Fuca1--*2)Gal epitope, which is the blood
group B determinant (11; see illustration in Fig. 1). It can be hypothesized that
the inability of anti-Gal from AB individuals to interact with the B antigen results
from an effective immune tolerance mechanism. Thus, in individuals with B or
AB blood type, tolerance prevents the production of anti-Gal clones capable of
interacting with the fucosylated Galal--*3Gal epitope (i.e., the B antigen). If this
assumption is correct, then this restrictive effect of immune tolerance should not
occur in individuals lacking the blood group B antigen. Therefore, in individuals
of blood type A or O (Table 1) the anti-Gal reactivity should include antibody
clones that can interact with both Galal--->3Gal and Gala 1--->3(Fucal--+2)Gal
epitopes as illustrated in Fig. 1. In the present study, we examine the extent by
which immune tolerance affects the spectrum of anti-Gal specificities produced
in individuals of different blood groups.
Materials and Methods
Isolation ofAnti-Galfrom Normal Human Serum.
￿
Anti-Gal was purified from normal
human serum by affinity chromatography according to a modification of the method
describedpreviously (10, 11). Heat-inactivated plasma was loaded on acolumn containing
the immunoadsorbent Synsorb 90 (Chembiomed, Edmonton, Canada) with the glycosidic
epitope Gala l--+3Gal#1-+4Glc-R. After extensive washing with PBS, the antibodies re-
tained on the column were eluted by incubation with 0.5 M melibiose (a-galactosyl
glucoside) for 4 h at 37°C. The carbohydrate was removed by repeated dialysis against
Bloodgroup Antigenicepitope on red cells Antibody in
the serum
A GalNAca1--*3(Fucal-~-2)Gal Anti-B
B GalaI-->3(Fucal-a2)Gal Anti-A
AB Galal~3(Fucal-~2)Gal None
GalNAca l~3(Fucal-2)Gal
O (H) Fucal~2Gal Anti-A
Anti-BGALILI ET AL.
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FIGURE 1 .
￿
Schematic representation of the interaction between anti-Gal and t
3Gal residue on CPH, or the Gala1--*3(Fuca1-*2)Gal residue of the blood group B antigen .
The hatched line represents the combining site ofpure anti-Gal fromAB or B sera which only
ith the Galal-+3Gal epitope . The dotted line represents the anti-Gal of A or O
y bind to the Galal--33Gal epitope with or without the branching fucose residue
penultimate galactosyl . The solid line represents the pure anti-B interacting exclusively
the Galal--33(Fuca1--o,2)Gal epitope.
large volumes of PBS . The anti-Gal preparation was brought to a concentration of 100
kg/ml in PBS . This concentration corresponds to the anti-Gal concentration of normal
human serum (10) .
Isolation ofAnti-A and Anti-B Antibodies .
￿
Sera containing anti-A or anti-B blood group
antibodies were incubated for 1 h at 24°C with equal volumes of washed packed A type
or B type red cells, respectively . The red cells were washed five times in 10 volumes of
PBS and lysed by hypotonic shock . After three additional washes, the antibodies adsorbed
the red cell membranes were eluted with glycine-HCI buffer (pH 2 .6) and brought
ediately to pH 7 .4 by addition of 1 N NaOH . The eluates were dialyzed against PBS
and the anti-blood group reactivity was assessed by hemagglutination with the relevant
red cells .
Glycosphingolipids .
￿
Globoside (Gb 4 ) was purchased from Supelco, Inc . (Bellefonte, PA) .
Human P, glycolipid was a gift from Drs . H . Clausen and S . Hakomori (Fred Hutchinson
Cancer Research Center, Seattle, WA) . B, glycolipid antigen was prepared from human
B red cells by Folch partitioning (12) and HPLC on an Iatrobead column using a gradient
of isopropanol/hexane/water (13) . All other glycosphingolipids were prepared in our
laboratory as previously reported (11, 14-16) .
Immunostaining of Glycosphingolipids on Thin-Layer Plates.
￿
Glycosphingolipids were
chromatographed on aluminum-backed Silica Gel 60 high-performance thin-layer
chromatography (HPTLC)' plates (E . M . Laboratories, Inc ., Cincinnati, OH) in
CHCI 3/MeOH/H 20 60/35/8 vol/vol . Immunostaining was done according to a modifï-
ion (17) of the method of Magnani et a1 . (18). The plate was dried and dipped (60 s)
solution of 0.1% polyisobutyl methylacrylate (Polysciences, Inc., Warrington, PA) in
and was air dried . The plate was soaked overnight at 5°C in PBS with 5% BSA,
"
￿
-` "
￿
aper.
￿
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for 2 h in anti-Gal or purified anti-B (5 jAg/ml), 1 h in biotinylated goat anti-human IgG
(Vector Laboratories, Inc., Burlingame, CA), and thereafter in the Vector ABC reagent
containing avidin-alkaline phosphatase, and finally in an alkaline phosphatase substrate
solution (Vector Laboratories, Inc., Burlingame, CA). The plate was rinsed for 10 min in
PBS between each incubation step.
Defucosylation ofthe B, Antigen.
￿
B, (10 jAg) was treated with 0.1 M TCA for 1 h at 80'C
to remove the fucose residue (19). After cooling, equal volumes of methanol and water
were added to the hydrolysate and the mixture was taken to dryness. The defucosylated
B, was resuspended in CHCI3/MeOH, 1/1 (vol/vol) and analyzed by TLC immunostaining
with anti-Gal.
Hemagglutination Assay.
￿
Indirect hemagglutination activity of the isolated antibodies
was titrated by mixing 50 tal of twofold serial dilutions of the antibody with an equal
volume of a 1 % red cell suspension in V-shaped wells of a microtiter plate. After a 30-
min incubation at room temperature, the red cells were washed three times by spinning
the plates for 3 min at 800 g, decantation of the supernatant, and resuspension of the
pelleted red cells. Thereafter, the red cells were resuspended in 50,ul rabbit anti-human
IgG antibodies (Dako, Copenhagen, Denmark). Agglutination was evaluated after the red
cells had settled at room temperature for 2 h. Titers were expressed as the greatest
dilution of antibody solution that caused complete agglutination.
Removal ofAnti-Gal Reactivityfrom Human Serum.
￿
The proportion ofanti-B antibodies
that have a crossreacting activity with anti-Gal was determined by analyzing anti-B activity
in sera depleted of anti-Gal. Adsorption of anti-Gal was performed by two methods: (a)
Adsorption of human A and O sera on rabbit red cells. These red cells lack the B antigen,
as indicated by the capacity of rabbits to produce anti-B antibodies (20), but express an
abundance of Gaal--*3Gal epitopes (21). Normal heat-inactivated A and O type sera
were mixed with an equal volume of packed rabbit red cells and incubated for 30 min at
room temperature. The red cells were removed by centrifugation and the procedure was
repeated three times. Thereafter, the adsorbed sera were assayed for anti-B reactivity by
hemagglutination assay with human B red cells. (b) Adsorption of human A and O sera
on a Gala l--*3Gal/31->4Glc-R immunoadsorbent column was used to remove anti-Gal
(Synsorb 90, Chembiomed, Edmonton, Canada). This procedure was repeated three
times. The anti-B reactivity remaining in the effluent after this procedure was assessed by
the hemagglutination assay.
Results
Demonstration ofthe Specificity ofthe Natural Anti-Gal Antibodies Isolatedfrom AB
Sera. In our previous study (10), we showed that anti-Gal isolated from normal
AB sera displays a distinct specificity for the Galal--+3Gal residue of the rabbit
CPH molecule, and not for the Gala l-~4Gal residue ofthe rabbit CTH molecule.
To further demonstrate the restricted specificity of this natural antibody a
number ofreference glycosphingolipids, listed in Table II, were studied for anti-
Gal binding. The interaction of anti-Gal with these compounds was analyzed by
immunostaining on TLC plates. In addition to the interaction with rabbit CPH
(Fig. 2, lane 2), anti-Gal bound to bovine CPH and CHH (Table II), all of which
have previously been shown to have terminal Galal-*3Ga1 residues (21-23).
Removal of the terminal galactosyl units by treatment with a-galactosidase
abolished the interaction with anti-Gal (not shown). Glycosphingolipids with
terminal Galal--*4Gal residues such as rabbit CTH and human P, antigen, or
glycosphingolipids with terminal Gal,Ql--*4GICNAc, or nongalactosyl terminal
carbohydrate residues, were not immunostained by anti-Gal (Table II). Further-
more, the presence of a branching fucose on the penultimate galactose residue
of Gala l-33GA (i.e., B, antigen) prevents anti-Gal binding (Fig. 2, lane 5) . TheName Source
GALILI ET AL .
TABLE II
Glycosphingolipids TestedforAnti-Gal Binding
Structure
FIGURE 2. Thin-layer chromatogram of red cell glycosphingolipids immunostained with
human anti-Gal and anti-B . (Lane 1) Rabbit glycosphingolipids stained with orcinol ; (lane 2)
rabbit glycosphingolipids immunostained with anti-Gal from AB serum ; (lane 3) human B,
glycosphingolipid from B type red cells stained with orcinol ; (lane 4)as in lane 3, immunostained
with purified anti-B antibodies ; (lane 5) as in lane 3, immunostained with anti-Gal from AB
serum ; (lane 6) defucosylated human B, glycosphingolipid stained with orcinol ; (lane 7) as in
lane 6, immunostained with anti-Gal from AB serum ; (lane 8) rabbit glycosphingolipids as in
lane 1, immunostained with anti-Gal fromA serum; (lane 9) human B, glycosphingolipid as in
lane 3, immunostained with anti-Gal fromA serum .
Anti-Gal
binding
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B antigenicity of this glycosphingolipid was demonstrated by immunostaining
with isolated human anti-B antibody (Fig . 2, lane 4) . Removal of the branching
fucosyl by mild acid treatment resulted in the comigration of the B l
derivative with CPH (Fig. 2, lane 6), and the immunostaining of this derivative
by anti-Gal (Fig. 2, lane 7) .
Differences in the Specificity of anti-Gal Isolated from the Serum of Individuals of
Various Blood Types. As shown in the previous section, the ability of anti-Gal
from AB serum to distinguish between the Galal--*3Gal epitope and the B
epitope was not surprising, since AB individuals lack any antibodies capable of
interacting with the B antigen as a result ofimmune tolerance (Table 1) . However,
we would expect A andO blood type individuals who lack the B antigen to have
anti-Gal clones interacting exclusively with the Gala1-->3Ga1 structure, and in
addition, anti-Gal clones interacting with the Galal--3Gal structure regardless
CPH (ceramidepentahexoside) Rabbit Galal-3Gaifll-+4GIcNAc#1-3GalO1-4GIc 1-ICer
CHH (ceramide heptahexoside) Cow GalaI-3(GalOI-4GIcNAc#1-3)2Gal#l-4GIc1-1Cer
Glucosyl ceramide Man Glc1-1Cer
Lactosyl ceramide Man Gal#1-4GIc 1-+lCer
CTH (ceramide tribexoside) Rabbit Galal~4Gal#1-4Gfcl~lCer
Gioboside Man/pig GaINAcol-s3Galtt1-4Gali3l-4Glci-ICer
Paragloboside Man Galpl-4GIeNAc$1-3Galp1-4GIcl-ICer
Forssman Sheep GaINAcal-3Ga1NAcpl-r3Galal-+4Galp1-4Glcl-ICer
P1 Man Galal-4Gaifll--4GIcNAc#1-3Ga1131~4Glc1-ICer
B, Man Gala1-+3(FucaI-2)Galpl-4G1cNAc$1-3Galp1-4GIc1-1Cer
GMs Man NeuAca2-r3GaIp1-4G1cl-1Cer
Sialylparagloboside Man NcuAca2~3Galp l~4GIcNAcp 1~3Galp l~4GIc l~1Cer698
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TABLE III
Hemagglutinating Reactivity* ofanti-Gal Isolatedfrom Individuals
ofVarious Blood Types$
Serum from
blood type
Hemagglutination titer
Rabbit RBC
￿
A type RBC$
￿
B type RBC§
A
￿
1:1,024
￿
-
￿
1:16
B
￿
1:512
￿
-
￿
-
AB 1:1,024
￿
-
￿
-
0
￿
1:512
￿
1:4
￿
1:32
* Indirect hemagglutination using rabbit anti-human IgG as a second
antibody.
$ Representative data of experiments performed with three to four indi-
viduals of each blood type.
§ Minus indicates no agglutination.
of whether a branching fucose is present or not (see illustration, Fig. 1). The
latter anti-Gal clones would thus immunostain both CPH and B, antigen. To test
this hypothesis, anti-Gal was isolated from the serum ofA type individuals by the
same method used for purifying anti-Gal from AB type donors (i.e., Galal--~'
3Gal immunoadsorbent affinity chromatography). Like anti-Gal from AB serum
(Fig. 2, lane 2), anti-Gal from A serum readily bound to rabbit CPH and to
rabbit glycosphingolipids with longer carbohydrate chains near the origin of the
TLC plate (Fig. 2, lane 8). These are neutral glycosphingolipids with long
complex carbohydrate chains (15-25 carbohydrate units) terminating in Galal--->
3Gal residues (24). However, unlike anti-Gal from AB serum, the anti-Gal from
A serum readily bound to the B, antigen (Fig. 2, lane 9) . These findings imply
that anti-Gal in A serum has a broader spectrum of specificity than anti-Gal in
AB serum. The anti-Gal in A serum consists of antibodies that recognize not
only Galal-a3Gal, but also Gala 1--*3(Fucal--~,2)Gal epitopes (see Fig. 1).
This conclusion was further supported by hemagglutination studies. Hemag-
glutination of B type red cells, whichexpress GalaI--3-3(FucaI-->2)Gal, and rabbit
red cells with Galal-*3Gal epitopes, was studied using anti-Gal prepared from
individuals of various blood types (Table III). It should be stressed that rabbit
red cells do not express the B antigenic epitope. As previously observed (10),
anti-Gal from all sera agglutinated rabbit red cells at a titer of 1:512 to 1 :1,024.
However, anti-Gal from A and O serum also agglutinated B type red cells,
whereas anti-Gal from B or AB serum had no such reactivity . The A type red
cells, used as control, were not agglutinated by anti-Gal from A, B, or AB sera.
A low hemagglutination titer of A red cells was observed with anti-Gal from O
serum. This finding suggests that anti-Gal produced in individuals lacking both
the A and B antigenic epitopes has a broader spectrum of specificity than anti-
Gal produced in individuals of other blood types. Thus, anti-Gal from O type
serum, which bound primarily to the Gala I--+3Gal epitope on the immunoadsor-
bent, contained antibody clones capable of interacting with the A and B antigenic
epitopes.
Anti-Gal Reactivity within Anti-B Antibodies. The results presented in the
previous section suggest that the anti-Gal antibodies of A and O blood type
individuals contain anti-B activity. To further demonstrate the overlap betweenFIGURE 3.
￿
Thin-layer chromatogram of bovine (lane 1), rabbit (lane 2), andhuman B (lane
3) red cell glycosphingolipids immunostained with purified human anti-B antibodies .
TABLE IV
Hemagglutinating Reactivity ofPurified Anti-A and Anti-B
Antibodies
Antibody type
Hemagglutination titer with :
Rabbit RBC*
￿
A type RBC
￿
B type RBC
Anti-A
￿
-
￿
1 :16 -
Anti-B
￿
1:16
￿
-
￿
1 :8
Purified antibodies were obtained by adsorption on the relevant red
cells, followed by acid elution of the absorbed antibodies .
* Minus indicates no agglutination .
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anti-Gal and anti-B reactivities in these individuals, purified anti-B was analyzed
for anti-Gal activity . Anti-B antibodieswere purified from A serum by adsorption
on and elution from B-type red cells . These anti-B antibodies were assayed for
anti-Gal activity by immunostaining glycosphingolipids with Galal-*3Ga1 epi-
topes . In addition to their reactivity with the B, antigen (Fig . 3, lane 3), these
antibodies readily bound to bovine and rabbit CPH (Fig . 3, lanes 1 and 2), and
to bovine CHH (Fig . 3, lane 1), all ofwhich have terminal Galal--*3Gal residue
(21-23) . The presence ofanti-Gal reactivity within the purified anti-B antibodies
was alsodemonstrated in hemagglutination studies (Table IV) . The anti-B eluates
agglutinated both B type red cells and rabbit red cells . Control experiments with
anti-A antibodies eluted from A red cells demonstrated a lack of agglutinating
reactivity with rabbit red cells . These results demonstrate that purified anti-B
antibodies also contain anti-Gal reactivity .
It was of interest to determine the proportion of anti-B antibodies with anti-
Gal reactivity versus that of pure anti-B [i.e ., reacting exclusively with the
Gala l-*3(Fucal--) ,2)Gal epitope] . For this purpose, sera of A and O type indi-
viduals that contain anti-B reactivity (Table 1) were adsorbed three times on
equal volumes of rabbit red cells to remove anti-Gal antibodies, then assayed by700
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TABLE V
Decrease in Anti-B Reactivity After Adsorption ofAnti-Gal
Discussion
* All sera were found to lack any agglutinating reactivity with rabbit red
cells afteradsorption on these redcells.
hemagglutination foralteration in anti-B reactivity. In parallel experiments, sera
were tested for anti-B reactivity before and after removal ofanti-Gal antibodies
by affinity chromatography on the Galal--3Gal immunoadsorbent. Both pro-
cedures resulted in the removal of >75% of anti-B reactivity, as indicated by a
decrease ofat least fourfold in the titer ofanti-B (Table V). These findings imply
that a large proportion of anti-B antibodies in normal human sera consist of
antibody clones that are reactive with both Gala1--3-3Gal and Galal-+3(FucaI--+
2)Gal structures. Although the proportion of these crossreactive antibodies
differs from one individual to another, the pure anti-B antibodies account for
<25% ofthe anti-B antibodies.
The results presented in the current study suggest that the spectrum of
specificities of a natural antibody produced against a given antigen is strictly
determined by the tolerance mechanism. This mechanism allows for the produc-
tion ofantibody clones with specificities toward a variety ofstructures other than
self antigens. Anti-Gal is produced in every individual and is defined as an
antibody that interacts with Galal--*3Gal epitopes. However, the spectrum of
anti-Gal specificity is dependent on the individual's blood type. Thus, B and AB
type individuals produce anti-Gal antibodies that only bind to Galal--3 .3Gal
epitopes; whereas A or O type individuals who lack the B epitope on their red
cells have clones of anti-Gal that bind to both Galal-*3Gal and the B antigen.
This was shown by immunochemical and hemagglutination analysis. Moreover,
adsorption experiments to remove anti-Gal indicated that the majority of the
antibodies designated anti-B are in fact anti-Gal clones that can also interact with
the Gala I->3(FucaI-*2)Gal epitope. Onlyasmall proportion ofanti-B antibodies
exclusivelyrecognizethe GalaI-->3(Fucal--+2)Gal epitope (pureanti-B illustrated
in Fig. 1). Thus, in contrast to the general view that anti-B antibodies are
immunoglobulin moleculesrecognizing the Galal-*3(Fucal-+2)Gal epitope, our
data indicate that anti-B is a heterogeneous antibody population that consists
mostly of antibodies recognizing both the B antigenic determinant and the
Galal--*3Gal epitope, and of a relatively small proportion of antibodies that
Anti-B Titer
Serum
donor Blood type Before ad-
Afterad-
sorption on After ad-
sorption rabbit red sorption on
cells* Synsorb90
YT A 1:128 1:8 1:16
XL A 1:64 1:2 1:2
SS A 1:64 1:8 1:16
UG 0 1:256 1:8 1:16
MR 0 1:256 1:16 1:32GALILI ET AL.
￿
701
exclusively bind to the Galal-~3(Fucal--+2)Gal epitope. The observation that
anti-B sera contain antibodies that interact with a structure that is distinct from
the B antigen but closely resembles it (B-like), was reported 60 yr ago by
Landsteiner and Philip-Miller (20, 25), and more recently by Owen (26). These
investigators made two apparently contradictory observations: (a) Rabbit red
cells can adsorb a large proportion, but not all, ofthe anti-B reactivity found in
A serum; and (b) that rabbits could produce anti-B antibodies after immunization
with B red cells. Thus, the antigen on rabbit red cells interacting with the anti-
B was designated a B-like antigen (26). Our data suggest that the B-like antigen
is the Galal--),3Gal epitope, which is abundantly expressed on rabbit red cells
and interacts with the anti-B antibodies that overlap with anti-Gal.
Anotherinteresting observation by Landsteiner and Philip-Miller (25) was that
the B-like antigen is expressed on red cells of New World monkeys, but not of
Old World monkeys or apes. This has been confirmed by others (27-29) who
showed that New World monkey red cells, like rabbit red cells, express a B-like
antigen that can adsorb only part ofhuman anti-B reactivity. Nevertheless, these
primates could produce antibodies to human B red cells. In a recent study (30,
31), we found that anti-Gal from AB sera interacts with red cells of New World
monkeys, but not with red cells of Old World monkeys or apes. Furthermore,
by immunostaining with anti-Gal, we demonstrated that New World monkey red
cells contain CPH with a Gala 1-).3Gal epitope, similar to that found in rabbit
and bovine red cells. These findings suggest that the Galal-+3Ga1 epitope is the
B-like antigenic determinant found in various mammals, including New World
monkeys.
The finding that anti-Gal and anti-B have overlapping reactivities suggests that
various clones ofanti-Gal display different degrees offitting to the Galal--*3Gal
structure (Fig. 1). This observation is in line with the elegant studies of Kabat
(8), whodemonstrated the occurrenceofclones ofhuman anti-dextran antibodies
with combining sites ofvarious sizes. Our study shows that a proportion ofanti-
Gal antibody clones crossreact with the B antigenic determinant. These clones
only exist in individuals in whom the B antigen is absent. In an individual
expressing the B antigen, such overlapping clones are absent due to immune
tolerance. The complete absence of anti-Gal clones capable ofreacting with self
blood group B antigen suggests that the immune tolerance mechanism exerts a
powerful effect, preventing the generation ofantibodies to selfantigens. Related
to this study are our recent observations on the contribution of anti-Gal to the
immune-mediated destruction of senescent and pathologic human red cells (10,
32-34). These studies have suggested that Galal--*3Gal epitopes are present on
human red cells in small amounts, and in a cryptic form. During the aging of
red cells in circulation, these epitopes become exposed de novo, which results in
anti-Gal binding to the red cells and their subsequent destruction. The occur-
rence of large amounts ofanti-Gal, and the presence ofits corresponding antigen
in a cryptic form suggests that immune tolerance is only effective with noncryptic
self antigens. Thus, the demonstration of natural antibodies to antigenic struc-
tures that are normally compartmentalized and not exposed to the immune
system (i.e., intracellularantigens orantigenson brain tissues) maynot contradict
the hypothesis that differentiation between self and nonself antigens is a result702
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ofimmunetolerance. Elucidation ofthe modebywhich this tolerance mechanism
functions, using precise immunochemical approaches such as described in the
present study, will greatly enhance the understanding of the basic processes in
the ontogeny ofthe immune system .
Summary
A well-defined antigen/antibody system was used to evaluate the effect of
immune tolerance on the spectrum of specificities of natural antibodies. The
antibody used in this study, anti-Gal, is a naturally occurring, polyclonal IgG that
constitutes 1% ofthe circulating IgG in humans. We have previously shown that
anti-Gal, purified from AB sera, specifically interacts with glycosphingolipids
bearing a Galal--*3Gal epitope, but not with the closely related B antigen in
which the penultimate galactose of the Galal-*3Gal epitope is fucosylated
Gala1--*3(Fuca1-*2)Gal. This narrow specificity was assumed to be the result of
an effective immune tolerance mechanism that prevents the expression of anti-
body clones that can recognize both the Galal--+3Gal and the self B epitopes. If
the assumption that immune tolerance determines the range ofanti-Gal specific-
ity is correct, then anti-Gal from individuals lacking the B antigen (A and O
blood types) would be expected to interact with both Galal->3Gal and Galal-->
3(Fucal--+2)Gal epitopes. In this study, anti-Gal from the serum of individuals
of various blood types was purified by affinity chromatography on Galal--*3Gal
adsorbent and tested for its reaction with the B antigen. Whereas anti-Gal from
AB and B individuals only reacted with Galal--+3Gal epitopes, anti-Gal from A
and Oindividuals reacted with both Galal-+3Gal and B epitopes. Furthermore,
it was determined that the majority ofanti-B reactivity in A and O individuals is
in fact anti-Gal antibodies capable of recognizing both Galal--*3Gal and B
epitopes. It can be concluded from theseresultsthatimmune toleranceaccurately
controls the spectrum of natural antibody specificities by preventing the produc-
tion ofantibody clones that can interact with selfantigens.
Receivedfor publication 13 November 1986.
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